Advertisement
Advertisement
U.S. Markets open in 3 hrs 18 mins
Advertisement
Advertisement
Advertisement
Advertisement

Zentalis Pharmaceuticals, Inc. (ZNTL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
23.60+0.10 (+0.43%)
At close: 04:00PM EST
24.78 +1.18 (+5.00%)
After hours: 05:18PM EST
Advertisement

Zentalis Pharmaceuticals, Inc.

1359 Broadway
Suite 1710
New York, NY 10018
United States
212 433 3791
https://zentalis.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees177

Key Executives

NameTitlePayExercisedYear Born
Dr. Kimberly Lynn Blackwell M.D.CEO & Director46.08kN/A1969
Mr. Cameron S. Gallagher M.B.A.Co-Founder, Pres & Director515.18kN/A1970
Dr. Kevin D. Bunker Ph.D.Co-Founder & Chief Scientific Officer648.84kN/A1972
Ms. Melissa B. Epperly M.B.A.CFO & Treasurer610.29kN/A1978
Adam LevySr. VP of Investor RelationsN/AN/AN/A
Ms. Andrea Paul J.D.Gen. Counsel & Corp. Sec.N/AN/A1981
Dr. Peter Huang Ph.D.Sr. VP of Discovery ResearchN/AN/AN/A
Dr. Meena Rao Ph.D.Sr. VP of Regulatory Affairs & Quality AssuranceN/AN/AN/A
Dr. Carrie Brownstein M.D.Chief Medical OfficerN/AN/A1970
Dr. Mark Lackner Ph.D.Chief Translational Officer & Head of Biomarker StrategyN/AN/A1967
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.

Corporate Governance

Zentalis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 8. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement